The authors found the association by comparing echocardiographic and biochemical changes after 5 years in patients with systemic lupus erythematosus (SLE). Lupus anticoagulant (LAC) may be a predictor ...

A retrospective study compared cardiovascular risks among patients with SLE who did and did not develop lupus nephritis and/or antiphospholipid antibody-positivity over time.

Credit: Shutterstock In a 5-year follow-up study, researchers identified the characteristics associated with cardiac function in patients with systemic lupus erythematosus. Lupus anticoagulant (LAC) ...

Please provide your email address to receive an email when new articles are posted on . To examine the relationship between antiphospholipid antibodies and future atherosclerotic cardiovascular ...

Atherosclerosis progression was more than twice as common in younger people with systemic lupus erythematosus (SLE) than in healthy controls in a prospective study from Greece, but the rate difference ...

Biomarkers that reliably identify or even predict disease manifestations in systemic lupus erythematosus (SLE) are needed. In a recent issue of the Clinical Journal of the American Society of ...

Among patients with new-onset systemic lupus erythematosus (SLE), 23% experienced one or more thromboembolic events (TEs). The incidence of TEs in antiphospholipid antibody-positive patients diagnosed ...

New research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, describes a link between positive antiphospholipid antibodies and an increased risk of future ...

Among patients with systemic lupus erythematosus (SLE), high titers of anti-phospholipid (aPL) antibodies were most prevalent in whites and Latinos and less so for Black and Asian individuals, ...